Literature DB >> 20697951

Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China.

Xiao-mei Hu1, Feng Liu, Rou Ma.   

Abstract

Chinese arsenic drugs have been applied in Chinese medicine for several centuries. Beginning from 1970s, arsenic containing drugs have been generally used for the treatment of malignant hematologic diseases including acute promyelocytic leukemia, myelodysplastic syndrome, and multiple myeloma. No matter what ingredients of arsenic drugs were applied, either arsenic trioxide, arsenic disulfide, or arsenic containing Chinese herbal compositions including Qinghuang Powder and Realgar-Indigo naturalis formula, they all provided the distinct approaches for the management of malignant hematologic diseases, and good clinical efficacy was obtained with mild adverse reactions. Moreover, the mechanisms of action have been continually elucidated.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20697951     DOI： 10.1007/s11655-010-0506-0

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN： 1672-0415            Impact factor:   1.978


  24 in total

1.  [Studies on red orpiment induction of NB4 and HL-60 cell apoptosis].

Authors:  Y Bai; S Huang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  1998-09

2.  Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.

Authors:  C Niu; H Yan; T Yu; H P Sun; J X Liu; X S Li; W Wu; F Q Zhang; Y Chen; L Zhou; J M Li; X Y Zeng; R R Yang; M M Yuan; M Y Ren; F Y Gu; Q Cao; B W Gu; X Y Su; G Q Chen; S M Xiong; T D Zhang; S Waxman; Z Y Wang; Z Chen; J Hu; Z X Shen; S J Chen
Journal:  Blood       Date:  1999-11-15       Impact factor: 22.113

3.  In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.

Authors:  G Q Chen; J Zhu; X G Shi; J H Ni; H J Zhong; G Y Si; X L Jin; W Tang; X S Li; S M Xong; Z X Shen; G L Sun; J Ma; P Zhang; T D Zhang; C Gazin; T Naoe; S J Chen; Z Y Wang; Z Chen
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

4.  [Therapeutic effects of combination of arsenic trioxide with low-dose all-trans retinoic acid on induction of remission acute promyeloeytic leukemia].

Authors:  Guan-jun Wang; Wei Li; Jiu-wei Cui; Su-jun Gao; Cheng Yao; Zhen-yu Jiang; Yan-qiu Song; Chang-ji Yuan; Yan Yang; Zi-ling Liu
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2005-04-27

5.  [A serial study of in cytogenetic change and morphology on the tetra-arsenic tetra-sulfide treatment in untreated or recurrent acute promyelocytic leukemia].

Authors:  Hui Liu; Jing-ying Qiu; Dao-pei Lu; Bo Hong; Hui-lin Shi; Yan Shi; Hui Dang; Qi He
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2003-03

Review 6.  Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.

Authors:  Z Chen; G Q Chen; Z X Shen; S J Chen; Z Y Wang
Journal:  Semin Hematol       Date:  2001-01       Impact factor: 3.851

7.  [Regulation of arsenic trioxide-inducing apoptosis].

Authors:  X Huang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  1999-05

8.  [Effects of arsenic trioxide on cell cycle and expression of cyclin dependent kinase inhibitors of multiple myeloma cells].

Authors:  Yu-bao Chen; Wei-jun Fu; Jian Hou; Si-qi Ding; Dong-xing Wang; Zhen-gang Yuan; Xian-tao Kong
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2003-04

Review 9.  Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.

Authors:  A List; M Beran; J DiPersio; J Slack; N Vey; C S Rosenfeld; P Greenberg
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

10.  [Inhibition effect of arsenic trioxide on the growth of human MDS cell line MUTZ-1 cells].

Authors:  Hong-yan Tong; Mao-fang Lin; Hong Xiong; Zhen Cai
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2004-01
View more
  9 in total

1.  Arsenic disulfide induced apoptosis and concurrently promoted erythroid differentiation in cytokine-dependent myelodysplastic syndrome-progressed leukemia cell line F-36p with complex karyotype including monosomy 7.

Authors:  Xiao-mei Hu; Sachiko Tanaka; Kenji Onda; Bo Yuan; Hiroo Toyoda; Rou Ma; Feng Liu; Toshihiko Hirano
Journal:  Chin J Integr Med       Date:  2014-03-07       Impact factor: 1.978

2.  Realgar quantum dots induce apoptosis and necrosis in HepG2 cells through endoplasmic reticulum stress.

Authors:  Y U Qin; Huan Wang; Zheng-Yun Liu; Jie Liu; Jin-Zhu Wu
Journal:  Biomed Rep       Date:  2015-07-15

3.  Absorption Characteristics of Combination Medication of Realgar and Indigo Naturalis: In Vitro Transport across MDCK-MDR1 Cells and In Vivo Pharmacokinetics in Mice after Oral Administration.

Authors:  Miao Zhang; Lin Guo; Long-Fei Lin; Chang-Hai Qu; Xing-Bin Yin; Shi-Lin Luo; Xin Zhang; Hai-Ying Zhang; Xiao Liang; Jun Guan; Jian Ni
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-06       Impact factor: 2.629

4.  Association of Gene Mutations with Response to Arsenic-Containing Compound Qinghuang Powder () in Patients with Myelodysplastic Syndromes.

Authors:  Pan Zhao; Jun-Bin Liang; Zhong-Yang Deng; Ming-Jing Wang; Jia-Yue Qin; Chong-Jian Chen; Xiao-Mei Hu
Journal:  Chin J Integr Med       Date:  2018-04-04       Impact factor: 1.978

5.  The Relationship between Traditional Chinese Medicine and Modern Medicine.

Authors:  Jingcheng Dong
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-30       Impact factor: 2.629

6.  Enhancing effects of indirubin on the arsenic disulfide-induced apoptosis of human diffuse large B-cell lymphoma cells.

Authors:  Ling Wang; Xianglu Li; Xinyu Liu; Kang Lu; N A Chen; Peipei Li; Xiao Lv; Xin Wang
Journal:  Oncol Lett       Date:  2015-02-09       Impact factor: 2.967

7.  Safety and efficacy of Compound Huangdai Tablets combined with all-trans retinoic acid for treatment of acute promyelocytic leukemia: Clinical evidence and potential mechanisms.

Authors:  Qianqian Huang; Tao Wang; Yan Xiong; Liping Qu; Qiaozhi Yin; Wenjun Zou
Journal:  Chin Herb Med       Date:  2021-09-13

Review 8.  Realgar (α-As4S4) Treats Myelodysplastic Syndromes through Reducing DNA Hypermethylation.

Authors:  Miao Zhang; Jia-Yi Zhang; Ming-Qian Sun; Peng Lu; Jian-Xun Liu
Journal:  Chin J Integr Med       Date:  2020-05-16       Impact factor: 1.978

Review 9.  Oral Arsenic-Containing Qinghuang Powder: A Potential Drug for Myelodysplastic Syndromes.

Authors:  Jing Ming; Wei-Yi Liu; Hai-Yan Xiao; Yong-Gang Xu; Rou Ma; Xiao-Mei Hu
Journal:  Chin J Integr Med       Date:  2020-03-07       Impact factor: 2.626
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.